Bausch + Lomb Corporation Reports Strong Q3 Results

NEW YORK – Bausch + Lomb Corporation (NYSE:BLCO) reported third-quarter revenue that exceeded analyst expectations and raised its full-year 2024 revenue guidance, driven by strong growth across all segments.

The eye health company posted revenue of $1.196 billion for the third quarter, surpassing the consensus estimate of $1.17 billion. Revenue grew 19% year-over-year on both a reported and constant currency basis.

Adjusted earnings per share came in at $0.13, missing analyst estimates of $0.16.

"Our focus on execution continues to drive growth, with significant opportunity ahead," said Brent Saunders, chairman and CEO of Bausch + Lomb. "We're in the middle of multi-dimensional launch cycles around the world, covering all our businesses and targeting all our audiences."

The company saw broad-based growth across all segments and geographies. Vision Care revenue rose 6% to $684 million, Surgical revenue increased 11% to $206 million, and Pharmaceuticals revenue surged 76% to $306 million.

Bausch + Lomb raised its full-year 2024 revenue guidance to a range of $4.725 billion to $4.825 billion, up from its previous outlook of $4.7 billion to $4.8 billion. The new guidance represents approximately 16-18% constant currency growth.

The company maintained its full-year adjusted EBITDA guidance excluding acquired in-process research and development of $850 million to $900 million.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.